Anastasios Stathis

8.0k total citations · 4 hit papers
198 papers, 4.9k citations indexed

About

Anastasios Stathis is a scholar working on Oncology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Anastasios Stathis has authored 198 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 93 papers in Oncology, 85 papers in Molecular Biology and 85 papers in Pathology and Forensic Medicine. Recurrent topics in Anastasios Stathis's work include Lymphoma Diagnosis and Treatment (84 papers), Chronic Lymphocytic Leukemia Research (47 papers) and Protein Degradation and Inhibitors (40 papers). Anastasios Stathis is often cited by papers focused on Lymphoma Diagnosis and Treatment (84 papers), Chronic Lymphocytic Leukemia Research (47 papers) and Protein Degradation and Inhibitors (40 papers). Anastasios Stathis collaborates with scholars based in Switzerland, Italy and United States. Anastasios Stathis's co-authors include Malcolm J. Moore, Francesco Bertoni, Emanuele Zucca, Franco Cavalli, Mohamed Békradda, Keyvan Rezaï, Jean‐Pierre Delord, Luciano Cascione, Chiara Tarantelli and Eugenio Gaudio and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Anastasios Stathis

189 papers receiving 4.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Advanced pancreatic carcinoma: current treatment and future challenges

2010 641 citations Anastasios Stathis et al. profile →
BET Proteins as Targets for Anticancer Treatment

2017 343 citations Anastasios Stathis, Francesco Bertoni Cancer Discovery profile →
Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study

2016 328 citations Anastasios Stathis, Patrice Herait et al. profile →
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial

2021 264 citations Paolo F. Caimi, Weiyun Z. Ai et al. profile →

Peers

Countries citing papers authored by Anastasios Stathis

Since Specialization

Citations

This map shows the geographic impact of Anastasios Stathis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anastasios Stathis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anastasios Stathis more than expected).

Fields of papers citing papers by Anastasios Stathis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anastasios Stathis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anastasios Stathis. The network helps show where Anastasios Stathis may publish in the future.

Co-authorship network of co-authors of Anastasios Stathis

This figure shows the co-authorship network connecting the top 25 collaborators of Anastasios Stathis. A scholar is included among the top collaborators of Anastasios Stathis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anastasios Stathis. Anastasios Stathis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Targeting CD25 + lymphoma cells with the antibody–drug conjugate camidanlumab tesirine as a single agent or in combination with targeted agents 2024 ·British Journal of Haematology ·Filippo Spriano, Chiara Tarantelli, (unknown), Eugenio Gaudio, Gaetanina Golino, Lorenzo Scalise, Maria Teresa Cacciapuoti, Emanuele Zucca, Anastasios Stathis, Patrick H. van Berkel, Giorgio Inghirami, Francesca Zammarchi, Francesco Bertoni	2
2	TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16) 2024 ·European Journal of Cancer ·Ilaria Colombo, (unknown), (unknown), Simon Haefliger, Manuela Rabaglio, Sara Bastian, (unknown), Katrin Eckhardt, Stefanie Hayoz, (unknown), Charlotte Kloft, (unknown), (unknown), Christian Baumgärtner, Cristiana Sessa, Anastasios Stathis, Dagmar Hess, Markus Joerger	10
3	Tafasitamab for the treatment of patients with diffuse large B-cell lymphoma 2024 ·Human Vaccines & Immunotherapeutics ·Maria Cristina Pirosa, Anastasios Stathis, Emanuele Zucca	5
4	Results of a phase 1, dose-finding study of Debio 0123 as monotherapy in adult patients with advanced solid tumors: Safety, pharmacokinetic, and preliminary antitumor activity data. 2024 ·Journal of Clinical Oncology ·Kyriakos P. Papadopoulos, Manish Sharma, Reinhard Dummer, Ilaria Colombo, Egle Ramelyte, Leigh G. Seamon, Drew Rasco, (unknown), (unknown), Tri Tat, (unknown), (unknown), (unknown), Sandrine Micallef, Anne Bellon, (unknown), Anastasios Stathis	5
5	A systematic review of contemporary phase I trials in patients with recurrent/metastatic head and neck cancer 2024 ·SHILAP Revista de lepidopterología ·Vittoria Espeli, Antonio Gómez, Panagiotis Balermpas, Giorgio Treglia, Anastasios Stathis	1
6	Antibody-drug conjugates combinations in cancer treatment 2024 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), Lucia Motta, Anastasios Stathis	4
7	Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors 2023 ·Investigational New Drugs ·Anastasios Stathis, Anthony W. Tolcher, (unknown), Daniel J. Renouf, Lin‐Chi Chen, (unknown), Tomoko Freshwater, Andrea L. Webber, Tapan K. Nayak, Lillian L. Siu	11
8	The ATR inhibitor elimusertib exhibits anti‐lymphoma activity and synergizes with the PI3K inhibitor copanlisib 2023 ·British Journal of Haematology ·Giulio Sartori, Chiara Tarantelli, Filippo Spriano, Eugenio Gaudio, Luciano Cascione, (unknown), Marilia Barreca, Alberto J. Arribas, (unknown), Gaetanina Golino, (unknown), Stefano Pileri, Giovanna Damia, Emanuele Zucca, Anastasios Stathis, Oliver Politz, Antje M. Wengner, Francesco Bertoni	7
9	Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study 2022 ·Blood Advances ·Juan Pablo Alderuccio, Weiyun Z. Ai, John Radford, Melhem Solh, Kirit M. Ardeshna, Matthew A. Lunning, Brian Hess, Pier Luigi Zinzani, Anastasios Stathis, Carmelo Carlo‐Stella, Mehdi Hamadani, Brad S. Kahl, David Ungar, (unknown), Eric Yu, (unknown), Paolo F. Caimi	1
10	Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA) 2022 ·Cancers ·Markus Joerger, Yannis Metaxas, Khalil Zaman, Olivier Michielin, Nicolas Mach, Adrienne Bettini, Andreas M. Schmitt, Nathan Cantoni, Clemens B. Caspar, (unknown), (unknown), Miklos Pless, Christian Britschgi, Christoph Renner, Dieter Koeberle, Jessica D. Schulz, Christoph Kopp, Stefanie Hayoz, Anastasios Stathis, Roger von Moos	3
11	Phase I Dose-Escalation Study of the Dual PI3K-mTORC1/2 Inhibitor Gedatolisib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors 2021 ·Clinical Cancer Research ·Ilaria Colombo, Sofia Genta, Federica Martorana, Monia Guidi, Milo Frattini, Eleftherios Pierre Samartzis, Simone Brandt, (unknown), (unknown), Mariarosa Pascale, Tatiana Terrot, Cristiana Sessa, Anastasios Stathis	27
12	Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors 2021 ·Blood Advances ·Afua A. Mensah, Filippo Spriano, Giulio Sartori, (unknown), Luciano Cascione, Eugenio Gaudio, Chiara Tarantelli, (unknown), Luca Aresu, Andrea Rinaldi, Giovanna Damia, Emanuela Lovati, Emanuele Zucca, Anastasios Stathis, Claudio Pietra, Francesco Bertoni	12
13	A systematic review of phase II trials exploring anti-PD-1/PD-L1 combinations in patients with solid tumors 2021 ·Cancer Treatment Reviews ·Federica Martorana, Ilaria Colombo, Giorgio Treglia, Silke Gillessen, Anastasios Stathis	10
14	SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model 2020 ·Blood Advances ·Luca Ceriani, Giuseppe Gritti, Luciano Cascione, Maria Cristina Pirosa, (unknown), (unknown), Anastasios Stathis, Andrea Bruno, Alden A. Moccia, Luca Giovanella, Stefanie Hayoz, Sämi Schär, Stefan Dirnhofer, Alessandro Rambaldi, Giovanni Martinelli, Christoph Mamot, Emanuele Zucca	57
15	Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma 2018 ·Blood ·Luca Ceriani, Lisa Milan, Maurizio Martelli, Andrés J.M. Ferreri, Luciano Cascione, Pier Luigi Zinzani, Alice Di Rocco, Annarita Conconi, Anastasios Stathis, Franco Cavalli, Monica Bellei, Kelly Cozens, (unknown), Luca Giovanella, Peter Johnson, Emanuele Zucca	72
16	Clinical Response of Carcinomas Harboring the BRD4–NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628 2016 ·Cancer Discovery ·Anastasios Stathis, Emanuele Zucca, Mohamed Békradda, Carlos Gomez‐Roca, Jean‐Pierre Delord, Thibault De La Motte Rouge, Emmanuelle Uro‐Coste, Filippo de Braud, Giuseppe Pelosi, Christopher A. French	268
17	Limited Benefit of Additional Contrast-Enhanced CT to End-of- Treatment PET-CT Evaluation in Patients with Follicular Lymphoma 2016 ·Blood ·Gaetano Paone, (unknown), Anastasios Stathis, Luca Giovanella, Emanuele Zucca, Luca Ceriani	1
18	The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs 2015 ·Clinical Cancer Research ·Michela Boi, Eugenio Gaudio, Paola Bonetti, Ivo Kwee, Elena Bernasconi, Chiara Tarantelli, Andrea Rinaldi, Monica Testoni, Luciano Cascione, Maurilio Ponzoni, Afua A. Mensah, Anastasios Stathis, Georg Stüssi, María E. Riveiro, Patrice Herait, Giorgio Inghirami, Esteban Cvitkovic, Emanuele Zucca, Francesco Bertoni	214
19	A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors 2014 ·Clinical Cancer Research ·Philippe L. Bédard, Josep Tabernero, Filip Jankú, Zev A. Wainberg, Luis Paz‐Ares, Johan Vansteenkiste, Eric Van Cutsem, José Manuel Pérez-García, Anastasios Stathis, Carolyn D. Britten, Ngocdiep T. Le, (unknown), David Demanse, Dénes Csonka, Malte Peters, Angela Zubel, Heidi Nauwelaerts, Cristiana Sessa	257
20	Phase I Study of Decitabine in Combination with Vorinostat in Patients with Advanced Solid Tumors and Non-Hodgkin's Lymphomas 2011 ·Clinical Cancer Research ·Anastasios Stathis, Sébastien J. Hotte, Eric X. Chen, Holger W. Hirte, Amit M. Oza, Patrícia Moretto, (unknown), (unknown), (unknown), (unknown), Lisa Wang, Wenjiang Zhang, Igor Espinoza‐Delgado, Julianne L. Holleran, Merrill J. Egorin, Lillian L. Siu	79

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact